European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
EANM Springer Prizes 2020 awarded at EANM 2021	244
Towards molecular imaging-guided intervention theatres in oncology	189
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?	158
New technologies—the best is yet to come	155
Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: “FROM HAMBURG WITH LOVE”	146
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands	139
Correction to: Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme	133
Cinematic rendering of [18F]FDG-PET/MR	129
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis	128
Low-dose dobutamine stress gated blood pool SPECT assessment of left ventricular contractile reserve in ischemic cardiomyopathy: a feasibility study	101
Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis	92
Simultaneous high-resolution whole-brain MR spectroscopy and [18F]FDG PET for temporal lobe epilepsy	90
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma	90
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study	88
Robust and generalizable artificial intelligence for multi-organ segmentation in ultra-low-dose total-body PET imaging: a multi-center and cross-tracer study	85
Cadherin-17 as a target for the immunoPET of adenocarcinoma	83
[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis	80
A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients	76
Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study	75
Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangli	73
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI	73
[18F]Fluorocholine PET/MRI and [18F]Fluorocholine PET/CT as first- and second-line imaging in primary hyperparathyroidism – who takes the lead?	72
68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results	71
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function	71
Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma	70

Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study	69
[68 Ga]Ga-FAPI versus [18F]F-FDG in malignant melanoma: complementary or counterpoint?	67
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation	65
Combination therapy of an 211At-labeled RGD peptide and immune checkpoint blockade to enhance antitumor efficacy	63
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review	63
Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer – Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/C	62
Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence	61
PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study	61
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?	61
Vancomycin-based tracers guiding in situ visualization of bacteria on osteosynthesis devices and surgical debridement	61
A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer	60
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2	58
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group	58
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard	57
Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer	56
Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers	55
Nuclear imaging and therapy in oncology in Poland in 2021–2022	51
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation	49
TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images — a multi-center generalizability analysis	49
[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia	49
Updated practice guideline for dual-energy X-ray absorptiometry (DXA)	48
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial	48
Seasonal variation in D2/3 dopamine receptor availability in the human brain	47
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer	47
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study	47
New horizons for the World Federation of Nuclear Medicine and Biology: achievements, partnerships, and future directions	46
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus	46
Abdelhamid H. Elgazzar, Synopsis of Pathophysiology in Nuclear Medicine, Second Edition	45
Andrea Varrone, Silvia Morbelli, Valentina Garibotto (Editors). Clinical nuclear medicine in neurology. An Atlas of challenging cases.	45
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study	45
Lisa Bodei, Jason S. Lewis, Brian M. Zeglis (Editors): Radiopharmaceutical Therapy	44
Promise of hypoxia-targeted tracers in metastatic lymph node imaging	44
Abnormal localized [18F]FDG accumulation in a Hoffman 3D brain phantom caused by Pseudomonas aeruginosa and Stenotrophomonas maltophilia	43
Development of STING probes and visualization of STING in multiple tumor types	43
Intense [68Ga]Ga-FAPI-04 uptake of pancreatic microcystic serous cystadenoma mimicking malignancy	43
Diffusely increased breast uptake of [18F]AlF-NOTA-FAPI-04 related to menstrual status in a patient with papillary thyroid cancer	43
Moganshan international consensus on further strengthening global scientific collaboration in the field of molecular imaging	42
[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors	42
Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in Parkinson’s disease	42
A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging	41
Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen	41
About ESTMABLE2: non-inferiority doesn’t equal better	41
Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued?	41
Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression	40
Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds	40
First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients	40
Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis	40
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	40
STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy	39
A cutting-edge technology for the future of nuclear medicine	39

Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer	39
Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	39
Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside	39
Correction to: FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis	39
Intraoperative molecular imaging of colorectal lung metastases with SGM-101: a feasibility study	38
DNA damage and repair in peripheral blood mononuclear cells after internal ex vivo irradiation of patient blood with 131I	38
Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer	38
Correction to: A bis-boron boramino acid PET tracer for brain tumor diagnosis	38
Comparative assessment of radiation therapy–induced vasculitis using [18F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy	38
A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients	38
[18F]-mFBG imaging for COVID-19-induced cardiac sympathetic innervation impairment	38
Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study	38
From radiotracer to radiopharmaceutical: a philosophical approach	38
Interpretable multimodal deep learning model for predicting post-surgical international society of urological pathology grade in primary prostate cancer	37
[68Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET/CT missed	37
An artificial intelligence-driven image quality assessment system for whole-body [18F]FDG PET/CT	37
Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective	37
Advancements in non-invasive visualization of the immune checkpoint TIGIT: a systematic review	37
Parkinson’s Disease-Related pattern in isolated REM sleep behaviour disorder as a prodromal progression marker: 8-Year Follow-Up changes assessed at three time points	36
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgk	36
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer	35
Bilateral intense [68 Ga]Ga-PSMA‑11 uptake in cyproterone acetate induced gynecomastia	35
Atypical [18F]FDG avidity in ALK-positive anaplastic large cell lymphoma: diagnostic and monitoring potential of [18F]FAPI PET/CT	35
Multi-modality deep learning-based [68Ga]Ga-DOTA-FAPI-04 PET polar map generation: potential value in detecting reactive fibrosis after myocardial infarction	35
Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography	35
Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: a proof-of-concept study	35
Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children	34
Synthesis, preclinical evaluation, and clinical translation of [68Ga]Ga-Asp2-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms	34
68Ga-DOTATOC digital-PET imaging of inflammatory cell infiltrates in myocarditis following COVID-19 vaccination	34
PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study	34
Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake	34
Distinguishing benign lesions from malignant ones using FAPI-based tracers: will we need to bid farewell to dual-time points imaging?	34
Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)	34
Comparison of two hybrid sentinel node tracers: indocyanine green (ICG)-99mTc-nanocolloid vs. ICG-99mTc-nanoscan from a nuclear medicine and surgical perspective	33
Deep learning-based image reconstruction and post-processing methods in positron emission tomography for low-dose imaging and resolution enhancement	33
Commentary to “[68 Ga]Ga-FAPI-04 PET/CT on assessing Crohn’s disease intestinal lesions” by Chen and colleagues	33
Guiding principles on the education and practice of theranostics	33
[18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer	33
Longitudinal evaluation of five nasopharyngeal carcinoma animal models on the microPET/MR platform	32
Disrupted gut microecology after high-dose 131I therapy and radioprotective effects of arachidonic acid supplementation	32
PET imaging of new target CDK19 in prostate cancer	32
Correction to: [18F]FDG brain PET findings in CLIPPERS at diagnosis and therapeutic follow-up	32
Distinct metabolic patterns of neuropsychiatric systemic lupus erythematosus on hierarchical cluster analysis	32
[177Lu]Lu-FAP-2286 therapy in ovarian neuroendocrine carcinoma: a promising theranostic approach	32
Prognostic role of metabolic parameters (MTV and TLG) of staging PET/CT in the pediatric population with Hodgkin’s lymphoma: an open discussion	32
Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease	32
Targeted alpha therapy: a comprehensive analysis of the biological effects from “local-regional-systemic” dimensions	32
Forearm metastasis as solitary manifestation of recurrent prostate cancer: A challenge for standard PSMA PET imaging protocol	32
Radioembolization of hepatocellular carcinoma with 90Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability	31
Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST	31
Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study	31
Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging	31
Molecular imaging: The bridge from human phenome to personalized precision medicine	31
PET/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak	31
Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study	31
Correction to: Deep learning for improving PET/CT attenuation correction by elastic registration of anatomical data	31
Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications	30
Visual grading for noninvasive assessment of transthyretin-related cardiomyopathy with bone scintigraphy: time for moving forward?	30
Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients	30
Assessing non-invasive quantitative methods for [18F]SynVesT-1 PET imaging of synaptic vesicle glycoprotein 2A in the rat brain	30
Pre-symptomatic scintigraphic and genetic cascade screening in cardiac transthyretin amyloidosis	30
Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios	30
Reply to Vaz et al., Editorial Commentary: Should “Heterogeneous response” be considered as new category for assessing treatment response in patients with breast cancer?	30
Radiofrequency ablation for autonomously functioning nodules as treatment for hyperthyroidism: subgroup analysis of toxic adenoma and multinodular goitre and predictors for treatment success	30
Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging	30
Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma—a retrospective cohort study	29
Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth	29
Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy	29
Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?	29
Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates	29
PET imaging utilization and trends in Germany: a comprehensive survey	29
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy	29
Hypermetabolic pulmonary lesions detection and diagnosis based on PET/CT imaging and deep learning models	28
European guidelines update on PSMA PET/CT for prostate cancer staging—snap back to reality	28
Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment del	28
Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts	28
Size-changeable nanoprobes for the combined radiotherapy and photodynamic therapy of tumor	28
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease	28
The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir	28
Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial	28

A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging	28
CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology	28
Multicentric development and evaluation of [18F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body r	28
The first international network symposium on artificial intelligence and informatics in nuclear medicine: “The bright future of nuclear medicine is illuminated by artificial intelligence”	28
Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication	28
Comparative analysis of [18F]F-FAPI PET/CT, [18F]F-FDG PET/CT and magnetization transfer MR imaging to detect intestinal fibrosis in Crohn’s disease: A prospective animal model and human cohort study	28
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study	28
Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images	27
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer	27
Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma	27
Intelligent ultrafast total-body PET for sedation-free pediatric [18F]FDG imaging	27
Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas	27
Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer	27
A comparative study of [68Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer	27
Can Q.Clear reconstruction be used to improve [68 Ga]Ga-DOTANOC PET/CT image quality in overweight NEN patients?	27
Association of PET vascular activity score with Takayasu’s arteritis angiographic progression	27
Comparison of the diagnostic value of [68 Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in patients with T stage ≤ 2a2 uterine cervical cancer: a prospective study	27
First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm	27
Collection on molecular imaging in cardiac amyloidosis	26
Impact of Tafamidis on [99mTc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects	26
Correction to: Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate	26
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer	26
Correction to: Modelling [18F]LW223 PET data using simplified imaging protocols for quantification of TSPO expression in the rat heart and brain	26
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology	26
Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer’s disease: insights from [18F]-florbetapir PET imaging	26
Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis	25
Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer	25
Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics	25
The value of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer	25
Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature	25
Impact of deep learning denoising on kinetic modelling for low-dose dynamic PET: application to single- and dual-tracer imaging protocols	25
Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics	25
New thresholds in semi-quantitative [18F]FDG PET/CT are needed to assess large vessel vasculitis with long-axial field-of-view scanners	25
PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers	25
The eye-black sign of lower eyelids related to R-CHOP therapy: a rare imaging pitfall	25
18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients	25
Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET/MR versus [18F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study	25
Myocardial perfusion SPECT findings in postCOVID period	25
Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles	25
Exploring the metabolic landscape of lung adenocarcinoma and squamous cell carcinoma: a total-body [18F]FDG PET/CT approach	25
DICOM header editing, between possibilities and regulatory bounds– 40 years of DICOM “standard”	25
Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET	25
[68Ga]Ga-FAPI PET/CT imaging of brown tumors in a patient with primary hyperparathyroidism	24
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis	24
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours	24
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis	24
Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation—results from a prospective pilot trial	24
Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis	24
Fibroblast activation Protein-Targeted PET/CT using [18 F]FAP-2286 for the evaluation of lung cancer: A comparative study with [18 F]FDG PET/CT	24
Abbreviated scan protocols to capture 18F-FDG kinetics for long axial FOV PET scanners	24
PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease	24
PET imaging of animal models with depressive-like phenotypes	24
Head-to-head comparison of [68 Ga]Ga-P16-093 and [68 Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients	24
Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies	23
Pleasurable music activates cerebral µ-opioid receptors: a combined PET-fMRI study	23
Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020	23
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI	23
Chlorin e6-loaded goat milk-derived extracellular vesicles for Cerenkov luminescence-induced photodynamic therapy	23
Total-body pediatric PET is ready for prime time	23
Comprehensive analysis of [18F]MFBG biodistribution normal patterns and variability in pediatric patients with neuroblastoma	23
Beyond 68Ga-labeled somatostatin analogues: is it time to say goodbye to [68Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?	23
Decoupling of regional neural activity and inter-regional functional connectivity in Alzheimer’s disease: a simultaneous PET/MR study	23
Lymph node classification in E-PSMA reporting guidelines for PSMA-PET	23
The role of radiographers in nuclear medicine; the link between patient and technology	23
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study	23
In vivo methods for imaging blood–brain barrier function and dysfunction	23
Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis	23
Expert consensus on workflow of PET/CT with long axial field-of-view	23
A. Zaheer, S.P. Raman, M.L. Rosado-de-Christenson, S. Martínez-Jiménez, S.H. Garrana, G. Fananapazir, D. Rogers, B.R. Foster: Imaging Anatomy: Chest, Abdomen, Pelvis, 3rd Edition	23
Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer	22
Prostate-specific membrane antigen radioguided surgery with negative histopathology: an in-depth analysis	22
Correction to: Hetero-bivalent agents targeting FAP and PSMA	22
Neuroimaging biomarkers in the biological definition of Parkinson’s disease and dementia with Lewy bodies – EANM position on current state, unmet needs and future perspectives	22
The effect of modern PET technology and techniques on the EANM paediatric dosage card	22
SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management—the EANM perspective	22
Exploring coronary microvascular function by quantitative CZT-SPECT: a small step or giant leap for INOCA patients?	22
Pigmented villonodular synovitis detected by [68Ga]Ga-FAPI-04 PET/CT	22
Positive amyloid and tau PET in an early-onset Alzheimer’s disease with a rare PSEN1 (Arg278Gly) mutation	22
An ultra-small organic dye nanocluster for enhancing NIR-II imaging-guided surgery outcomes	22
Loss of synaptic density in nucleus basalis of meynert indicates distinct neurodegeneration in Alzheimer’s disease: the RJNB-D study	22
Dania Tamimi (Editor) Specialty imaging: Temporomandibular Joint and Sleep-Disordered Breathing, 2nd Edition	22
L.J. Koenig, D. Tamimi, S.E. Perschbacher, H. Demirturk. Diagnostic imaging: oral and maxillofacial. 3rd Edition	22
Eribulin improves tumor oxygenation demonstrated by 18F-DiFA hypoxia imaging, leading to radio-sensitization in human cancer xenograft models	22
Individual cerebellar metabolic connectome in patients with MTLE and NTLE associated with surgical prognosis	22
Correction To: Coronary artery calcium measurement on attenuation correction computed tomography using artificial intelligence: correlation with coronary flow capacity and prognosis	22
Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate	22
Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study	21
New opportunities for dosimetric approach in patients with differentiated thyroid cancer	21
Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer	21
[18F]FDG PET/CT imaging in a patient with diffuse skeletal muscle metastasis of thyroid carcinoma	21
Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [18F]FET PET, and TSPO PET	21
Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)	21
Impressive FDG PET/CT image of extensive peripheral nervous system involvement for T-lymphoblastic leukemia/lymphoma	21
James F. Griffith. Diagnostic ultrasound: musculoskeletal, 3rd edition. Elsevier, 2025, ISBN: 9780443285646	21
High-resolution pediatric age–specific 18F-FDG PET template: a pilot study in epileptogenic focus localization	21